Go Pro
→ The 1934 playbook (From American Alternative) (Ad)tc pixel Free AIXC Stock Alerts

Qualigen Therapeutics (AIXC) Competitors

Qualigen Therapeutics logo
$1.01 +0.02 (+2.20%)
As of 01:45 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

AIXC vs. BTMD, HRTX, ENTX, RLYB, and RNTX

Should you buy Qualigen Therapeutics stock or one of its competitors? MarketBeat compares Qualigen Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Qualigen Therapeutics include biote (BTMD), Heron Therapeutics (HRTX), Entera Bio (ENTX), Rallybio (RLYB), and Rein Therapeutics (RNTX). These companies are all part of the "pharmaceutical products" industry.

How does Qualigen Therapeutics compare to biote?

Qualigen Therapeutics (NASDAQ:AIXC) and biote (NASDAQ:BTMD) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk, institutional ownership and media sentiment.

3.2% of Qualigen Therapeutics shares are owned by institutional investors. Comparatively, 21.7% of biote shares are owned by institutional investors. 1.2% of Qualigen Therapeutics shares are owned by insiders. Comparatively, 32.4% of biote shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

biote has a net margin of 8.29% compared to Qualigen Therapeutics' net margin of 0.00%. biote's return on equity of -25.72% beat Qualigen Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Qualigen TherapeuticsN/A -771.52% -79.52%
biote 8.29%-25.72%15.12%

biote has a consensus target price of $2.75, suggesting a potential upside of 21.74%. Given biote's stronger consensus rating and higher probable upside, analysts plainly believe biote is more favorable than Qualigen Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Qualigen Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
biote
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.50

biote has higher revenue and earnings than Qualigen Therapeutics. Qualigen Therapeutics is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Qualigen TherapeuticsN/AN/A-$16.97M-$6.47N/A
biote$192.22M0.44$27.05M$0.445.13

Qualigen Therapeutics has a beta of 0.49, meaning that its stock price is 51% less volatile than the broader market. Comparatively, biote has a beta of 1.66, meaning that its stock price is 66% more volatile than the broader market.

In the previous week, biote had 1 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 4 mentions for biote and 3 mentions for Qualigen Therapeutics. biote's average media sentiment score of 1.37 beat Qualigen Therapeutics' score of 0.06 indicating that biote is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Qualigen Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
biote
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

biote beats Qualigen Therapeutics on 16 of the 16 factors compared between the two stocks.

How does Qualigen Therapeutics compare to Heron Therapeutics?

Qualigen Therapeutics (NASDAQ:AIXC) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Qualigen Therapeutics has a net margin of 0.00% compared to Heron Therapeutics' net margin of -20.53%. Qualigen Therapeutics' return on equity of -771.52% beat Heron Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Qualigen TherapeuticsN/A -771.52% -79.52%
Heron Therapeutics -20.53%-7,747.30%-8.94%

3.2% of Qualigen Therapeutics shares are owned by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are owned by institutional investors. 1.2% of Qualigen Therapeutics shares are owned by company insiders. Comparatively, 6.1% of Heron Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Qualigen Therapeutics has higher earnings, but lower revenue than Heron Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Qualigen TherapeuticsN/AN/A-$16.97M-$6.47N/A
Heron Therapeutics$154.90M0.52-$20.19M-$0.18N/A

Qualigen Therapeutics has a beta of 0.49, indicating that its stock price is 51% less volatile than the broader market. Comparatively, Heron Therapeutics has a beta of 1.65, indicating that its stock price is 65% more volatile than the broader market.

Heron Therapeutics has a consensus price target of $2.50, indicating a potential upside of 489.62%. Given Heron Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Heron Therapeutics is more favorable than Qualigen Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Qualigen Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Heron Therapeutics
2 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Qualigen Therapeutics had 1 more articles in the media than Heron Therapeutics. MarketBeat recorded 3 mentions for Qualigen Therapeutics and 2 mentions for Heron Therapeutics. Heron Therapeutics' average media sentiment score of 1.08 beat Qualigen Therapeutics' score of 0.06 indicating that Heron Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Qualigen Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Heron Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Heron Therapeutics beats Qualigen Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Qualigen Therapeutics compare to Entera Bio?

Entera Bio (NASDAQ:ENTX) and Qualigen Therapeutics (NASDAQ:AIXC) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

Entera Bio has a beta of 1.43, suggesting that its stock price is 43% more volatile than the broader market. Comparatively, Qualigen Therapeutics has a beta of 0.49, suggesting that its stock price is 51% less volatile than the broader market.

Entera Bio has higher revenue and earnings than Qualigen Therapeutics. Entera Bio is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Entera Bio$40K2,168.76-$11.44M-$0.27N/A
Qualigen TherapeuticsN/AN/A-$16.97M-$6.47N/A

Entera Bio's return on equity of -83.31% beat Qualigen Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Entera BioN/A -83.31% -70.83%
Qualigen Therapeutics N/A -771.52%-79.52%

Entera Bio presently has a consensus target price of $9.00, indicating a potential upside of 411.36%. Given Entera Bio's stronger consensus rating and higher possible upside, analysts clearly believe Entera Bio is more favorable than Qualigen Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Entera Bio
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Qualigen Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

14.1% of Entera Bio shares are owned by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are owned by institutional investors. 10.6% of Entera Bio shares are owned by company insiders. Comparatively, 1.2% of Qualigen Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Entera Bio and Entera Bio both had 3 articles in the media. Qualigen Therapeutics' average media sentiment score of 0.06 beat Entera Bio's score of -0.13 indicating that Qualigen Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Entera Bio
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Qualigen Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Entera Bio beats Qualigen Therapeutics on 11 of the 13 factors compared between the two stocks.

How does Qualigen Therapeutics compare to Rallybio?

Rallybio (NASDAQ:RLYB) and Qualigen Therapeutics (NASDAQ:AIXC) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rallybio
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Qualigen Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Qualigen Therapeutics has a net margin of 0.00% compared to Rallybio's net margin of -911.07%. Rallybio's return on equity of -55.79% beat Qualigen Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Rallybio-911.07% -55.79% -51.48%
Qualigen Therapeutics N/A -771.52%-79.52%

Rallybio has higher revenue and earnings than Qualigen Therapeutics. Rallybio is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rallybio$860K99.47-$8.98M-$4.34N/A
Qualigen TherapeuticsN/AN/A-$16.97M-$6.47N/A

90.3% of Rallybio shares are held by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are held by institutional investors. 10.3% of Rallybio shares are held by company insiders. Comparatively, 1.2% of Qualigen Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Rallybio and Rallybio both had 3 articles in the media. Rallybio's average media sentiment score of 0.88 beat Qualigen Therapeutics' score of 0.06 indicating that Rallybio is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Rallybio
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Qualigen Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Rallybio has a beta of -0.9, meaning that its share price is 190% less volatile than the broader market. Comparatively, Qualigen Therapeutics has a beta of 0.49, meaning that its share price is 51% less volatile than the broader market.

Summary

Rallybio beats Qualigen Therapeutics on 8 of the 11 factors compared between the two stocks.

How does Qualigen Therapeutics compare to Rein Therapeutics?

Rein Therapeutics (NASDAQ:RNTX) and Qualigen Therapeutics (NASDAQ:AIXC) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

Rein Therapeutics has a beta of 1.35, meaning that its share price is 35% more volatile than the broader market. Comparatively, Qualigen Therapeutics has a beta of 0.49, meaning that its share price is 51% less volatile than the broader market.

Rein Therapeutics' return on equity of 0.00% beat Qualigen Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Rein TherapeuticsN/A N/A -68.14%
Qualigen Therapeutics N/A -771.52%-79.52%

In the previous week, Rein Therapeutics had 1 more articles in the media than Qualigen Therapeutics. MarketBeat recorded 4 mentions for Rein Therapeutics and 3 mentions for Qualigen Therapeutics. Rein Therapeutics' average media sentiment score of 0.89 beat Qualigen Therapeutics' score of 0.06 indicating that Rein Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Rein Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Qualigen Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

90.9% of Rein Therapeutics shares are held by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are held by institutional investors. 1.5% of Rein Therapeutics shares are held by company insiders. Comparatively, 1.2% of Qualigen Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Rein Therapeutics currently has a consensus target price of $7.00, indicating a potential upside of 644.68%. Given Rein Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Rein Therapeutics is more favorable than Qualigen Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rein Therapeutics
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Qualigen Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Rein Therapeutics is trading at a lower price-to-earnings ratio than Qualigen Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rein TherapeuticsN/AN/A-$49.87M-$1.90N/A
Qualigen TherapeuticsN/AN/A-$16.97M-$6.47N/A

Summary

Rein Therapeutics beats Qualigen Therapeutics on 11 of the 13 factors compared between the two stocks.

Get Qualigen Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AIXC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AIXC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AIXC vs. The Competition

Export
MetricQualigen TherapeuticsPharmaceutical Preparations IndustryManufacturing SectorNASDAQ Exchange
Market Cap$20.48M$942.99M$4.37B$12.59B
Dividend YieldN/A4.84%30.61%8.43%
P/E Ratio-0.161.5823.7224.33
Price / SalesN/A116.93142.2092.04
Price / CashN/A20.06165.4759.39
Price / Book-1.358.5712.256.30
Net Income-$16.97M-$3.40M$120.20M$331.45M
7 Day Performance-3.62%-2.06%-1.05%-0.08%
1 Month Performance-26.13%-1.07%-3.10%-0.96%
1 Year PerformanceN/A35.25%11.05%19.89%

Qualigen Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AIXC
Qualigen Therapeutics
0.1545 of 5 stars		$1.01
+2.2%		N/AN/A$20.48MN/AN/A50
BTMD
biote
4.6799 of 5 stars		$2.26
+0.4%		$2.75
+21.7%		-45.8%$84.93M$192.22M5.14194
HRTX
Heron Therapeutics
2.3051 of 5 stars		$0.45
+4.7%		$2.50
+461.2%		-79.7%$84.32M$154.90MN/A300
ENTX
Entera Bio
1.8678 of 5 stars		$1.69
+1.8%		$9.00
+432.5%		-10.0%$83.30MN/AN/A20
RLYB
Rallybio
0.8746 of 5 stars		$15.68
+0.1%		N/A+376.5%$83.10M$860KN/A40

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:AIXC) was last updated on 7/15/2026 by MarketBeat.com Staff.
From Our Partners
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel
Elon’s new "tollbooth"
The SpaceX IPO was valued at $1.75 trillion. But one analyst says fighting over those shares may be the wrong ...
Weiss Ratings | Sponsoredtc pixel